Literature DB >> 19633876

Trigeminal neurinomas: clinical features and surgical experience in 84 patients.

Xiao-Dong Liu1, Qi-Wu Xu, Xiao-Ming Che, De-Ling Yang.   

Abstract

Trigeminal neurinomas are the second most common intracranial neurinomas next to the vestibular neurinomas. Eighty-four patients with trigeminal neurinomas were treated between 2003 and 2007. There were 40 women and 44 men (mean age 43 years). The most frequent symptoms were headache or numbness of the ipsilateral hemiface. There were 24 type A, nine type B, 45 type C, and six type D tumors. Dextroscope virtual reality technology was used for preoperative planning in recent eight cases. Gross total resection was achieved in 63 patients. We found that the major impediments to complete removal were adherent to the brainstem and skull base vascular structure, the frontotemporal approach with zygomatic or orbitozygomatic osteotomy or subtemporal approach could offer excellent exposure of the middle fossa and access to the posterior fossa, and Dextroscope virtual reality technology was a very useful tool to identify surgical and anatomic nuances and enhance preoperative planning in trigeminal neurinomas resection.

Entities:  

Mesh:

Year:  2009        PMID: 19633876     DOI: 10.1007/s10143-009-0210-8

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  38 in total

1.  Planning and simulation of neurosurgery in a virtual reality environment.

Authors:  R A Kockro; L Serra; Y Tseng-Tsai; C Chan; S Yih-Yian; C Gim-Guan; E Lee; L Y Hoe; N Hern; W L Nowinski
Journal:  Neurosurgery       Date:  2000-01       Impact factor: 4.654

2.  Some aspects of trigeminal neurinomas.

Authors:  L R Mello; A Tänzer
Journal:  Neuroradiology       Date:  1972-12       Impact factor: 2.804

Review 3.  Trigeminal schwannoma. Surgical series of 14 cases with review of the literature.

Authors:  P C McCormick; J A Bello; K D Post
Journal:  J Neurosurg       Date:  1988-12       Impact factor: 5.115

4.  Trigeminal neurinomas. A series of 111 surgical cases from a single institution.

Authors:  A N Konovalov; A Spallone; D J Mukhamedjanov; V A Tcherekajev; U B Makhmudov
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

5.  Virtual reality augmentation in skull base surgery.

Authors:  Steffen K Rosahl; Alireza Gharabaghi; Ulrich Hubbe; Ramin Shahidi; Madjid Samii
Journal:  Skull Base       Date:  2006-05

6.  Comparison of conventional and skull base surgical approaches for the excision of trigeminal neurinomas.

Authors:  J M Taha; J M Tew; H R van Loveren; J T Keller; M el-Kalliny
Journal:  J Neurosurg       Date:  1995-05       Impact factor: 5.115

7.  Varied appearance of trigeminal neuroma on CT.

Authors:  R Goldberg; S Byrd; J Winter; M Takahashi; P Joyce
Journal:  AJR Am J Roentgenol       Date:  1980-01       Impact factor: 3.959

8.  Trigeminal neuroma. A report of eleven cases.

Authors:  L Bordi; J Compton; L Symon
Journal:  Surg Neurol       Date:  1989-04

9.  Frontotemporal epidural approach to trigeminal neurinomas.

Authors:  V V Dolenc
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

10.  Surgical treatment of dumbbell-shaped neurinomas: report of an experience with 57 cases in a single hospital.

Authors:  Liang-Fu Zhou; Ying Mao; Rong Zhang
Journal:  Surg Neurol       Date:  2007-12
View more
  2 in total

1.  A suggestion of modified classification of trigeminal schwannomas according to location, shape, and extension.

Authors:  Seong Kyun Jeong; Eun Jung Lee; Yun Hee Hue; Young Hyun Cho; Jeong Hoon Kim; Chang Jin Kim
Journal:  Brain Tumor Res Treat       Date:  2014-10-31

Review 2.  Trends in the Management of Non-Vestibular Skull Base and Intracranial Schwannomas.

Authors:  Carlos Suárez; Fernando López; William M Mendenhall; Simon Andreasen; Lauge Hjorth Mikkelsen; Johannes A Langendijk; Stefano Bondi; Juan P Rodrigo; Leif Bäck; Antti A Mäkitie; Verónica Fernández-Alvarez; Andrés Coca-Pelaz; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Manag Res       Date:  2021-01-18       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.